Research Article

Long-Term Administration of Angiotensin (1–7) to db/db Mice Reduces Oxidative Stress Damage in the Kidneys and Prevents Renal Dysfunction

Anna Malgorzata Papinska1 and Kathleen Elizabeth Rodgers1,2

1School of Pharmacy, University of Southern California, 1985 Zonal Ave., Los Angeles, CA 90033, USA
2School of Medicine, Center for Innovation in Brain Sciences, University of Arizona, 1230 N. Cherry Ave., Tucson, AZ 85721, USA

Correspondence should be addressed to Kathleen Elizabeth Rodgers; krodgers@email.arizona.edu

Received 18 July 2018; Revised 4 September 2018; Accepted 11 September 2018; Published 23 October 2018

Copyright © 2018 Anna Malgorzata Papinska and Kathleen Elizabeth Rodgers. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aims. The goal of this study was to evaluate the effects of long-term (16 weeks) administration of angiotensin (1–7) [A(1–7)] on kidney function in db/db mice and to identify the protective mechanisms of this therapy.

Methods. db/db mice and heterozygous controls were treated with A(1–7) or vehicle daily, subcutaneously for up to 16 weeks. Kidney injury was assessed by measuring blood flow in renal arteries, plasma creatinine levels, and proteinuria. Effects of treatment on oxidative stress were evaluated by histological staining and gene expression.

Results. 16 weeks of daily administration of A(1–7) to a mouse model of severe type 2 diabetes (db/db) prevented the progression of kidney damage. Treatment with A(1–7) improved blood flow in the renal arteries, as well as decreased plasma creatinine levels and proteinuria in diabetic mice. Reduction of oxidative stress was identified as one of the mechanisms of the renoprotective action of A(1–7). Treatment prevented formation of nitrotyrosine residues, a marker of oxidative stress damage. A(1–7) also reduced the expression of two enzymes involved in formation of nitrotyrosine, namely, eNOS and NOX-4. A(1–7) regulated the phosphorylation pattern of eNOS to enhance production of NO in diabetic animals, possibly through the Akt pathway. However, these elevated levels of NO did not result in increased nitrosylation, possibly due to reduced NOX-4 levels.

Conclusions. Long-term administration of A(1–7) improved kidney function and reduced oxidative stress damage in db/db mice.

1. Introduction

Over 100,000 US citizens are diagnosed with kidney failure yearly and 44% of them are due to diabetes [1]. A central therapeutic strategy to prevent complications in patients with T2D is to reduce the activity of the pathological arm of the renin-angiotensin system (RAS), namely, levels and actions of angiotensin II (Ang-II). Ang-II has been implicated as a key factor in T2D pathology; however, the exact mechanism is not fully understood. Nonetheless, Ang-II has been shown to cause hypertension [2, 3], inflammation [4, 5], and oxidative stress [3, 6, 7] and contribute to insulin resistance [8, 9]. Thus, the current treatment for diabetic nephropathy focuses on angiotensin-converting enzyme inhibitors (ACEi), which reduce the production of Ang-II, and angiotensin receptor blockers (ARBs), which block the actions of Ang-II through its cognate receptor, AT1. However, both therapies are associated with adverse effects, are not safe to use during pregnancy [10, 11], and do not completely eliminate kidney damage. It is hypothesized that angiotensin (1–7) [A(1–7)], another member of the RAS, can ameliorate diabetic nephropathy without the side effects of ACEi or ARBs. A(1–7) has been shown to decrease hypertension and oppose pathological actions of Ang-II [12, 13]. Here, we demonstrate that long-term administration of A(1–7) to db/db mice, a model of severe T2D, acts renoprotective, at least in part, through the amelioration of oxidative stress.

Hyperglycemia, as well as high levels of cytokines and other growth factors, contributes to increased oxidative stress, which leads to numerous diabetic complications...
including nephropathy. Elevated levels of reactive oxygen species (ROS) may result in promotion of fibrosis, inflammation, and endothelial dysfunction in diabetic kidneys [14–17]. Studies show increased circulating levels of ROS in diabetes in both animals and patients [15, 18]. The main source of ROS in diabetic kidneys is thought to be NOX-4, a member of the NADPH oxidase family. Superoxide produced by this enzyme, when combined with nitric oxide (NO), results in the formation of peroxynitrite—a very potent ROS that has the capability to modify proteins to form nitrotyrosine (N-Tyr). Addition of the nitrate groups to the proteins changes their structure and function and may result in pathologies [19, 20].

Studies also show that A(1–7) [21] as well as its receptor Mas [22] are expressed in renal tissue in relatively high amounts and the peptide can be detected in urine [23]. This suggests that A(1–7) may play a role in kidney homeostasis. A(1–7) acts renoprotective in several models of kidney dysfunction [24, 25]. Studies of renal biopsies from patients with diabetic nephropathy also show an increased ACE/ACE2 ratio, which suggests increased production of Ang-II and decreased production of A(1–7). However, some studies show progression of kidney disease with A(1–7) treatment. For example, in streptozotocin-diabetic rats and in a non-diabetic model of unilateral ureteral obstruction [26], treatment with A(1–7) was not beneficial. These controversies have still not been fully explained; however, some of the discrepancies are being ascribed to dosage and route of administration. It is therefore crucial to further study the effects of A(1–7) on diabetic nephropathy to elucidate the mechanisms of possible protective action of this treatment.

2. Materials and Methods

2.1. Animal Procedures. We followed the methods of Papinska et al. [27].

All animal procedures were carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the US National Institutes of Health.

Eight-week-old male BKS.Cg-Dock7m */+ Leprdb/db (db/db) mice and age-matched heterozygous controls (non-diabetic) were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Mice were randomized based on the initial weight into four treatment groups (n = 6/group). Animals were kept on a 12 h light/dark cycle and food and water were available ad libitum.

Animals were administered either vehicle (saline) or A(1–7) (0.5 mg/kg/day) subcutaneously, daily for 16, 12, or 4 weeks. Previous dose finding studies performed in this laboratory revealed that 0.5 mg/kg/day, once daily, is the optimal dosing regimen, with no further benefit at 1 mg/kg/day [28, 29]. Pharmaceutical grade A(1–7) was purchased from Bachem (Torrance, CA, USA). At the necropsy, animals were overdosed with ketamine and xylazine cocktail followed by thoracotomy.

2.2. Ultrasonographic Assessment of Blood Flow Velocity in Renal Artery. Blood flow velocity in the renal arteries was assessed noninvasively using a high-frequency, high-resolution ultrasound system consisting of a Vivid 7 Dimension ultrasound machine equipped with a 6–13 MHz linear transducer (GE Healthcare, Little Chalfont, UK) after 16 weeks of treatment. Fur from the abdomen was removed using a hair removal cream. Anesthesia was induced with 3% isoflurane in an induction chamber. The mouse was then placed in a supine position on a heating pad to maintain body temperature at 36.5–37°C. Anesthesia was maintained through a nosecone and adjusted to maintain the heart rate at 450–550 beats per minute. The probe was positioned on the side of the abdomen to allow visualization of the cross section of the right kidney. Peak systolic blood flow velocity was measured using pulsed-wave Doppler in the renal artery just before it enters the kidney, as described previously [30]. Doppler measurements were then analyzed by a blinded observer.

2.3. Plasma and Urine Creatinine Concentration. Blood was collected from each animal at the necropsy through a cardiac puncture into EDTA-coated tubes. Immediately after collection, plasma was isolated by centrifugation and stored at −80°C until analysis. Urine samples were collected in the morning of the day preceding the necropsy. Creatinine concentration in the plasma and urine samples was measured using a Mouse Creatinine Kit (Crystal Chem, Downers Grove, IL) per the manufacturer’s instructions.

2.4. Urine Protein Concentration. Protein concentration in urine samples was assessed using standard Bradford assay. BSA was used as a standard. The samples were incubated with Bradford reagent (Bio-Rad, Hercules, CA) for 10 min at room temperature and spectrophotometrically analyzed using a BioTek Synergy H1 Hybrid plate reader (BioTek, Winooski, VT). Protein concentration was normalized to urine creatinine levels.

2.5. Glomerular Hypertrophy and Mesangial Expansion. After 16 weeks of treatment, the kidneys were isolated, formalin-fixed, paraffin-embedded, and cut at 5 μm. To assess glomerular hypertrophy and mesangial expansion, the sections were stained using the periodic acid-Schiff (PAS) method. Twenty images of random cortical glomeruli were obtained at 40x magnification. The images were analyzed in a blinded fashion using ImageJ (1.47v, NIH, USA). Glomerular area was measured using a free-hand selection tool, and staining was assessed using color-deconvolution plugin and threshold function. The mesangial expansion was expressed as percentage of glomerular area stained with PAS.

2.6. Immunohistochemistry for N-Tyr, p-eNOS, and NOX-4. Kidney sections were treated using a standard heat-induced antigen retrieval procedure. The slides were incubated with (a) rabbit polyclonal antibody directed against nitrided tyrosine residues (EMD Millipore, Billerica, MA) at 1 : 250 dilution, (b) rabbit polyclonal antibody to p-eNOS Ser1177 (GeneTex Inc., Irvine, CA) at 1 : 100 dilution, (c) rabbit polyclonal antibody to p-eNOS Thr495 (Bioss Inc., Woburn, MA) at 1 : 100 dilution, and (d) rabbit polyclonal antibody to NOX-4 (EMD Millipore, Billerica, MA) at 1 : 200 dilution.
After incubation with a proper secondary antibody, an avidin-biotin complex method of detection was used. Twenty random images of renal cortex at 40x were evaluated for the extent of staining in a blinded fashion using ImageJ (1.47v, NIH, USA) and expressed as percentage of area positively stained.

2.7. Gene Expression. At the necropsy, left kidneys were isolated and stored in RNALater (Thermo Fisher Scientific, Waltham, MA) at −20°C until use. qRT-PCR was performed as described previously [28]. Briefly, RNA was isolated using TRIzol reagent (Invitrogen by Thermo Fisher Scientific, Waltham, MA) and reverse-transcribed, and real-time PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems by Life Technologies, Thermo Fisher Scientific, Waltham, MA). Relative expression of each of the genes of interest was evaluated using an ABI 7300 instrument (Applied Biosystems by Life Technologies, Thermo Fisher Scientific, Waltham, MA). Abundance of targeted mRNA was normalized against 29S mRNA.

2.8. Statistical Analysis. We followed the methods of Papinska et al. [27].

GraphPad Prism version 6.0c for Mac OS X (GraphPad Software, San Diego, CA, USA) was used to analyze the data. One-way ANOVA followed by Dunnett’s multiple-comparison test were used to compare data. The level of statistical significance was set at 5%. Data are expressed as mean value ± standard error of the mean (SEM).

3. Results

3.1. 16 Weeks of A(1–7) Administration Reduces Shear Stress and Improves Kidney Function and Glomerular Structure in Diabetic Mice. The blood flow velocity in the renal artery was measured using ultrasonography. Treatment with A(1–7) reduced the blood flow velocity in renal arteries of diabetic mice (Figure 1(a)). db/db mice also had decreased kidney function as measured by creatinine levels in plasma and protein/creatinine ratio in urine (Figures 1(a) and 1(c)). Both of these parameters were decreased after treatment with A(1–7).

The glomerular structure was assessed by measuring glomerular hypertrophy and mesangial expansion. Both glomerular hypertrophy and the mesangial expansion were increased in kidneys from diabetic animals. A(1–7) reduced glomerular remodeling in db/db mice (Figure 1(d)–1(f)). No significant differences were seen between heterozygous (nondiabetic) groups [treated with A(1–7) or vehicle], which is also true for all the other parameters presented in this study.

3.2. Oxidative Stress Damage in Diabetic Kidneys Was Decreased after Administration of A(1–7). NADPH oxidase, one of the main sources of superoxide anion in diabetic kidney, is directly activated by Ang-II. We evaluated oxidative stress-induced damage in the kidney sections using an anti-nitrotyrosine- (N-Tyr-) directed antibody. The extent of staining in the kidneys from diabetic mice treated with placebo was increased compared to nondiabetic animals (Figure 2). Administration of A(1–7) significantly reduced the presence of this marker, which suggests decreased oxidative stress damage in the kidneys.

3.3. Administration of A(1–7) Altered Gene Expression of eNOS and NADPH Oxidase. eNOS is one of the main sources of NO in the kidneys. N-Tyr is formed due to increased levels of peroxynitrite, which is produced through reaction of NO with superoxide anion (Figure 3). We evaluated the expression of the two main enzymes that produce these molecules—eNOS and p22-phox (subunit of NADPH oxidase). Gene expression was performed on tissues collected from animals treated for either 4 or 12 weeks. Even though we did not observe any changes in the expression of these enzymes after 12 weeks of treatment (Figures 4(c) and 4(d)), there was a significantly increased expression of both eNOS and p22-phox in the kidneys of diabetic animals treated with the vehicle for 4 weeks compared to heterozygous mice (Figures 4(a) and 4(b)). Administration of A(1–7) reduced the gene expression of both of these enzymes in diabetic mice.

3.4. A(1–7) Alters the Phosphorylation Pattern of eNOS and Reduces Levels of NOX-4. eNOS can be activated or deactivated through modification of the two main phosphorylation sites: phosphorylation of eNOS on Ser1177 and dephosphorylation on Thr495 activate eNOS to produce NO. We evaluated effects of A(1–7) on the eNOS phosphorylation pattern using immunohistochemistry. The phosphorylation on Ser1177 was increased in both db/db groups [treated with vehicle or A(1–7)] (Figures 5(a) and 5(b)), whereas the phosphorylation on Thr495 was increased in diabetic animals treated with saline and reduced after treatment with A(1–7) (Figures 5(a) and 5(c)).

NOX-4 is the most prevalent form of NADPH oxidase in the kidneys and the main source of superoxide [31]. We evaluated the levels of NOX-4 in the kidney sections collected from animals treated for 16 weeks. Expression of NOX-4 was increased in the kidneys from diabetic animals treated with the vehicle as compared to heterozygous mice (Figures 5(a) and 5(d)). A(1–7) reduced the extent of staining for NOX-4 in db/db mice.

4. Discussion

Here, we show that the long-term administration of A(1–7) is effective in preventing oxidative stress damage and renal dysfunction in db/db mice. It is important to note that, so far, ACEi and ARBs even though able to slow down the progression of diabetic nephropathy are not recommended for prevention of kidney disease. As demonstrated previously, the treatment regimen presented in this article does not have any effects on blood glucose levels or body weight in this mouse model [27]. Thus, the effects of A(1–7) on the kidney’s health occurred independently of blood glucose or obesity control.

In this study, A(1–7) reduced the blood flow velocity through the renal artery, which may have contributed to decreased shear stress in the kidneys and improved renal...
function. The increased levels of creatinine in plasma from diabetic animals treated with saline suggest impaired filtration function of the kidneys, whereas increased protein/creatinine ratio in the urine implies structural changes in the glomeruli. Treatment with A(1–7) reduced both of these parameters in the diabetic mice. Benter and colleagues showed similar results of Ang(1–7) treatment on renal function in streptozotocin-induced diabetes in rats [32, 33]. In this study, Ang(1–7) as well as its nonpeptide analog AVE0991 reduced proteinuria and improved vascular
responsiveness of isolated ring segments from renal arteries. Mesangial expansion is another highlight of renal pathology in T2D. Mesangial cells produce excessive amounts of extracellular matrix, which reduces flexibility of the glomeruli and decreases surface area available for filtration. A(1–7) decreased mesangial expansion and glomerular hypertrophy, which might have contributed to enhancement of kidney function in diabetic animals.

Oxidative stress can be caused by both hyperglycemia and activation of the pathological arm of the RAS. Since peroxynitrite is one of the most potent oxidants, increased production of this molecule can lead to formation of N-Tyr and result in structural and functional changes to the proteins. Both NO and superoxide are needed to produce N-Tyr. We observed increased mRNA expression of both eNOS and p22-phox, a subunit of NADPH oxidase, in the kidneys from diabetic animals treated for 4 weeks but not in the kidneys from animals treated for 12 weeks. We hypothesize that the reason for this discrepancy is that the gene expression changes are an acute response to the stimuli. As anticipated, A(1–7) reduced the gene expression of both of these markers after 4 weeks of treatment, suggesting decreased production of both NO and superoxide at this time point. No significant changes after 16 weeks of treatment were anticipated, and therefore, this analysis was not performed.

The activation of eNOS is controlled through posttranslational changes such as phosphorylation. Increased phosphorylation of eNOS on Ser1177 in both diabetic groups suggests enhanced production of NO in these animals. We hypothesize that increased phosphorylation of eNOS on...
Thr495 observed in the diabetic group given the vehicle is associated with a defense mechanism that acts against the overproduction of ROS. In addition, phosphorylation on Ser1177 is known to be primarily associated with activation of the Akt pathway, which is involved in insulin signaling and is known to have a protective role in T2D [34, 35]. In contrast, activation of the PKC pathway, which is detrimental in diabetes [36], has been described as the main source of phosphorylation on Thr495. Increased phosphorylation on Thr495 in db/db mice from the placebo group may therefore be associated with increased activation of the PKC pathway. Further, reduction of the levels of phosphorylation at this amino acid suggests reduction in PKC activity in diabetic animals treated with A(1–7). High blood glucose is known to activate the PKC pathway, which is associated with overexpression of TGF-β, fibronectin, and collagen type IV; over time, this causes mesangial expansion [37].

In addition to enhanced activation of eNOS, kidneys from diabetic animals also showed increased expression of NOX-4, the most predominant type of NADPH oxidase in the kidneys, an enzyme responsible for cytosolic production of superoxide anion [31]. NADPH oxidase was initially discovered to be present in neutrophils and play a role in response to pathogens by producing high levels of ROS. In the kidneys, this enzyme is also located in nonphagocytic cell types such as mesangial cells, proximal tubules, vascular smooth muscle cells, endothelium, and fibroblasts [38]. It is thought that the primary role of ROS produced by the NADPH oxidase in the kidneys is to act as a secondary messenger. However, in pathological states, such as T2D, NADPH oxidase produces highly excessive amounts of ROS. Thus, NADPH oxidase contributes to oxidative stress damage in various renal pathologies including diabetic nephropathy [16, 39]. Overexpression of both p22-phox and NOX-4 subunits has been previously associated with diabetic nephropathy [40, 41]. In addition, inhibition of NADPH oxidase with apocynin was shown to reduce kidney damage and mesangial expansion in diabetic nephropathy [16, 40, 42]. In db/db mice, NOX-4 is involved in molecular mechanisms underlying renal fibrosis through increased TGF-beta and fibronectin production [38]. NADPH oxidase can also be activated via phosphorylation of PKC in diabetic

![Figure 4: Gene expression of eNOS and NADPH oxidase in the kidneys from animals treated for 4 or 12 weeks. Gene expression of both eNOS and p22-phox (subunit of NADPH oxidase) was increased in diabetic animals after 4 weeks of treatment (animals were 12 weeks old) (a, b). Treatment with A(1–7) reduced the expression of both of these markers. No significant differences in gene expression of eNOS and p22-phox were detected in animals treated for 12 weeks (20 weeks old). (hzg: heterozygous; n = 6 animals per group; *p < 0.05 and **p < 0.01) Calculated using one-way ANOVA; plotted as mean with SEM.](image-url)
kidneys [16]. Even though intracellular ROS may come from various sources, NOX-4 is thought to be a source of superoxide in the diabetic kidneys [31, 43]. NOX-4 has been recently shown to constitutively produce hydrogen peroxide in contrast to other forms of NOX that primarily produce superoxide; however, research showed that NOX-4 is in fact capable of releasing both hydrogen peroxide and superoxide [44]. Because treatment with A(1–7) reduced the levels of NOX-4 and decreased tyrosine nitration, we hypothesize that this is one of the major pathways that contribute to decreased oxidative stress damage in the kidneys. These findings are also consistent with work published by Benter and colleagues, who showed that A(1–7) administration to a rat model of streptozotocin-induced diabetes reduced activity of renal NADPH oxidase and decreased expression of NOX-4 [33]. Similarly, Dhaunsi et al. showed that Ang(1–7) can be effective in reducing NADPH oxidase activity in diabetic kidney [40].

Our findings are consistent with several recent studies in the field. Mori and colleagues showed that constant infusion of A(1–7) via implanted micro-osmotic pumps reduced renal hypertrophy and reduced mesangial expansion in older (5-6...
months old) db/db mice [45]. The authors associated renoprotective effects of A(1–7) to reduction in oxidative stress, inflammation, fibrosis, and lipotoxicity. Giani and colleagues also demonstrated improved renal health in Zucker diabetic fatty rats treated with A(1–7) through a micro-osmotic pump for 2 weeks [46]. In this study, administration of Ang(1–7) reduced renal fibrosis, triglyceridermia, and proteinuria and improved creatinine clearance through reduction of blood pressure, oxidative stress, and inflammation.

Overall, A(1–7) may represent a novel, safer treatment for diabetic nephropathy. In contrast to ACEi and ARBs, A(1–7) activates the protective arm of the RAS. A(1–7) was shown to have positive effects on kidney cells even in the absence of a hemodynamic factor [47, 48]. Here, we confirm that long-term administration of A(1–7) in a severe model of T2D results in prevention of kidney damage and improved filtration function. One of the mechanisms involved in this renoprotective action is the amelioration of oxidative stress. We have also shown that administration of A(1–7) to healthy mice has virtually no effects on the kidneys. Clinical studies showed that A(1–7) is also safe in patients [49]. This allows for the rapid translation of our preclinical results into potential clinical evaluation.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Acknowledgments

Authors would like to thank Isabela Galvez for her help with analysis of PAS staining, Sofia Santos for assistance in gene expression assays, and Chris Meeks for help with ultrasound measurements. The authors would also like to thank Dr. Sachin Jadhav, Maira Soto, Alick Tan, Lila Kim, and Tamar Cohen-Amzaleg for their help with animal handling and necropsies. This study was funded in part by the National Institutes of Health (Grant No. 5R01HL082722-02).

References

[1] US Renal Data System, USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007.
[2] J. C. Romero and J. F. Reckelhoff, "Role of angiotensin and oxidative stress in essential hypertension," *Hypertension*, vol. 34, no. 4, pp. 943–949, 1999.
[3] M. C. Zimmerman, E. Lazartigues, R. V. Sharma, and R. L. Davison, "Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system," *Circulation Research*, vol. 95, no. 2, pp. 210–216, 2004.
[4] D. N. Muller, R. Dechend, E. M. A. Mervaala et al., "NF-kB inhibition ameliorates angiotensin II–induced inflammatory damage in rats," *Hypertension*, vol. 35, no. 1, pp. 193–201, 2000.
[5] Y. Suzuki, M. Ruiz-Ortega, O. Lorenzo, M. Ruperez, V. Esteban, and J. Egidio, "Inflammation and angiotensin II," *The International Journal of Biochemistry & Cell Biology*, vol. 35, no. 6, pp. 881–900, 2003.
[6] T. Chabrashvili, C. Kityakara, J. Blau et al., "Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression," *American Journal of Physiology. Regulatory, Integrative and Comparative Physiology*, vol. 285, no. 1, pp. R117–R124, 2003.
[7] S. Rajagopalan, S. Kurz, T. Münzel et al., "Angiotensin II–mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone," *The Journal of Clinical Investigation*, vol. 97, no. 8, pp. 1916–1923, 1996.
[8] E. J. Henriksen, "Improvement of insulin sensitivity by antagonism of the renin-angiotensin system," *American Journal of Physiology. Regulatory, Integrative and Comparative Physiology*, vol. 293, no. 3, pp. R974–R980, 2007.
[9] J. A. Olivares-Reyes, A. Arellano-Plan carte, and J. R. Castillo-Hernandez, "Angiotensin II and the development of insulin resistance: implications for diabetes," *Molecular and Cellular Endocrinology*, vol. 302, no. 2, pp. 128–139, 2009.
[10] J. B. Kostis, B. Shelton, G. Gosselin et al., "Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD)," *American Heart Journal*, vol. 131, no. 2, pp. 350–355, 1996.
[11] Y. Lacourcière, A. Bélanger, C. Godin et al., "Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy," *Kidney International*, vol. 58, no. 2, pp. 762–769, 2000.
[12] W. O. Sampaio, C. Henrique de Castro, R. A. S. Santos, E. L. Schiffrin, and R. M. Touyz, "Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells," *Hypertension*, vol. 50, no. 6, pp. 1093–1098, 2007.
[13] C. M. Ferrario, M. C. Chappell, E. A. Tallant, K. B. Brosnihan, and D. I. Diz, "Counterregulatory actions of angiotensin-(1-7)," *Hypertension*, vol. 30, no. 3, pp. 535–541, 1997.
[14] A. Avogaro, S. V. de Kreutzbenz, and G. P. Fadini, "Oxidative stress and vascular disease in diabetes: is the dichotomization of insulin signaling still valid?," *Free Radical Biology and Medicine*, vol. 44, no. 6, pp. 1209–1215, 2008.
[15] A. Tojo, K. Asaba, and M. L. Onozato, "Suppressing renal NADPH oxidase to treat diabetic nephropathy," *Expert Opinion on Therapeutic Targets*, vol. 11, no. 8, pp. 1011–1018, 2007.
[16] V. Thallas-Bonke, S. R. Thorpe, M. T. Coughlan et al., "Inhibition of NADPH oxidase prevents advanced glycation end product–mediated damage in diabetic nephropathy through a protein kinase C–α-dependent pathway," *Diabetes*, vol. 57, no. 2, pp. 460–469, 2008.
[17] Y. Gorin, K. Block, J. Hernandez et al., "Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney," *The Journal of Biological Chemistry*, vol. 280, no. 47, pp. 39616–39626, 2005.
[18] M. R. Yun, D. S. Im, J.-S. Lee et al., "NAD(P)H oxidase-stimulating activity of serum from type 2 diabetic patients with retinopathy mediates enhanced endothelial expression of E-selectin," *Life Sciences*, vol. 78, no. 22, pp. 2608–2614, 2006.
[19] R. Radi, "Protein tyrosine nitration: biochemical mechanisms and structural basis of functional effects," *Accounts of Chemical Research*, vol. 46, no. 2, pp. 550–559, 2013.

[20] P. Pacher, I. G. Obrosova, J. G. Mabley, and C. Szabo, "Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies," *Current Medicinal Chemistry*, vol. 12, no. 3, pp. 267–275, 2005.

[21] K. D. Pendergrass, N. T. Pirro, B. M. Westwood, C. M. Fer- rario, K. B. Brosnihan, and M. C. Chappell, "Sex differences in circulating and renal angiotensins of hypertensive mRen().-Lewis but not normotensive Lewis rats," *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 295, no. 1, pp. H10–H20, 2008.

[22] T. Y. M. Gwashney, B. M. Westwood, N. T. Pirro et al., "Nuclear angiotensin-(1–7) receptor is functionally coupled to the formation of nitric oxide," *American Journal of Physiology-Renal Physiology*, vol. 299, no. 5, pp. F983–F990, 2010.

[23] N. Li, J. Zimpelmann, K. Cheng, J. A. Wilkins, and K. D. Burns, "The role of angiotensin converting enzyme 2 in the generation of angiotensin I–7 by rat proximal tubules," *American Journal of Physiology-Renal Physiology*, vol. 288, no. 2, pp. F353–F362, 2005.

[24] I. F. Benter, M. H. M. Yousif, J. T. Anim, C. Cojocel, and D. I. Diz, "Angiotensin-(1–7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME," *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 290, no. 2, pp. H684–H691, 2006.

[25] J. F. Giani, M. C. Muñoz, M. A. Mayer et al., "Angiotensin-(1–7) improves cardiac remodeling and inhibits growth-promoting pathways in the heart of fructose-fed rats," *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 298, no. 3, pp. H1003–H1013, 2010.

[26] V. Esteban, S. Heringer-Walther, A. Sterner-Kock et al., "Angiotensin-(1–7) and the G protein-coupled receptor mas are key players in renal inflammation," *PLoS One*, vol. 4, no. 4, article e5406, 2009.

[27] A. M. Papinska, M. Soto, C. J. Meeks, and K. E. Rodgers, "Long-term administration of angiotensin (1–7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathologi- cal remodeling," *Pharmacological Research*, vol. 107, pp. 372–380, 2016.

[28] N. M. Mordwinkin, C. J. Meeks, S. S. Jadhav et al., "Angioten- sin-(1–7) administration reduces oxidative stress in diabetic bone marrow," *Endocrinology*, vol. 153, no. 5, pp. 2189–2197, 2012.

[29] A. M. Papinska, N. M. Mordwinkin, C. J. Meeks, S. S. Jadhav, and K. E. Rodgers, "Angiotensin-(1-7) administration benefits cardiac, renal and progenitor cell function in db/db mice," *British Journal of Pharmacology*, vol. 172, no. 18, pp. 4443–4453, 2015.

[30] E. I. Boesen, G. R. Crislap, and J. C. Sullivan, "Use of ultrasound to assess renal reperfusion and P-selectin expression following unilateral renal ischemia," *American Journal of Physiology-Renal Physiology*, vol. 303, no. 9, pp. F1333–F1340, 2012.

[31] P. S. Gill and C. S. Wilcox, "NADPH oxidases in the kidney," *Antioxidants & Redox Signaling*, vol. 8, no. 9-10, pp. 1597–1607, 2006.

[32] I. F. Benter, M. H. M. Yousif, C. Cojocel, M. al-Maghebre, and D. I. Diz, "Angiotensin-(1–7) prevents diabetes-induced cardiovascular dysfunction," *American Journal of Physiology. Heart and Circulatory Physiology*, vol. 292, no. 1, pp. H666–H672, 2007.

[33] I. F. Benter, M. H. M. Yousif, G. S. Dhaunsi, J. Kaur, M. C. Chappell, and D. I. Diz, "Angiotensin-(1–7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats," *American Journal of Nephrology*, vol. 28, no. 1, pp. 25–33, 2008.

[34] T. Kobayashi, K. Taguchi, T. Yasuhiro, T. Matsumoto, and K. Kamata, "Impairment of P13-K/Akt pathway underlies attenuated endothelial function in aorta of type 2 diabetic mouse model," *Hypertension*, vol. 44, no. 6, pp. 956–962, 2004.

[35] R. W. A. Mackenzie and B. T. Elliott, "Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes," *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, vol. 2014, no. 7, pp. 55–64, 2014.

[36] D. Koya and G. L. King, "Protein kinase C activation and the development of diabetic complications," *Diabetes*, vol. 47, no. 6, pp. 859–866, 1998.

[37] D. Koya, M. R. Irousek, Y. W. Lin, H. Ishii, K. Kuboki, and G. L. King, "Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanooids in the glomeruli of diabetic rats," *Journal of Clinical Investigation*, vol. 100, no. 1, pp. 115–126, 1997.

[38] M. Sedeek, G. Callera, A. Montezano et al., "Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy," *American Journal of Physiology-Renal Physiology*, vol. 299, no. 6, pp. F1348–F1358, 2010.

[39] J. M. Forbes, M. T. Coughlan, and M. E. Cooper, "Oxidative stress as a major culprit in kidney disease in diabetes," *Diabete*, vol. 57, no. 6, pp. 1446–1454, 2008.

[40] G. S. Dhaunsi, M. H. M. Yousif, S. Akhtar, M. C. Chappell, D. I. Diz, and I. F. Benter, "Angiotensin-(1–7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities," *European Journal of Pharmacology*, vol. 638, no. 1–3, pp. 108–114, 2010.

[41] J. M. Li and A. M. Shah, "ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy," *Journal of the American Society of Nephrology*, vol. 14, no. 9003, pp. 2215–2226, 2003.

[42] K. Asaba, A. Tojo, M. L. Onozato et al., "Effects of NADPH oxidase inhibitor in diabetic nephropathy," *Kidney International*, vol. 67, no. 5, pp. 1890–1898, 2005.

[43] J. T. Hancock, R. Desikan, and S. J. Neill, "Role of reactive oxy- gen species in cell signalling pathways," *Biochemical Society Transactions*, vol. 29, no. 2, pp. 345–349, 2001.

[44] Y. Nisimoto, B. A. Diebold, D. Cosentino-Gomes, and J. D. Lambeth, "Nox-4: a hydrogen peroxide-generating oxygen sen- sor," *Biochemistry*, vol. 53, no. 31, pp. 5111–5120, 2014.

[45] J. Mori, V. B. Patel, T. Ramprashat et al., "Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by re- ducing oxidative stress, inflammation, and lipotoxicity," *American Journal of Physiology. Renal Physiology*, vol. 306, no. 8, pp. F812–F821, 2014.

[46] J. F. Giani, V. Burghi, L. C. Veiras et al., "Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats,"
Z. Su, J. Zimpelmann, and K. D. Burns, “Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells,” Kidney International, vol. 69, no. 12, pp. 2212–2218, 2006.

E. Gava, A. Samad-Zadeh, J. Zimpelmann et al., “Angiotensin-(1–7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells,” Nephrology Dialysis Transplantation, vol. 24, no. 6, pp. 1766–1773, 2009.

K. E. Rodgers, J. Oliver, and G. S. diZerega, “Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer,” Cancer Chemotherapy and Pharmacology, vol. 57, no. 5, pp. 559–568, 2006.